

RECEIVED
NOV 09 2001
TECH CENTER 1600/2900
PATENT
Docket No. 500862002100
Clk Ref: REDC-2110

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, D.C. on November 8, 2001.

Name: Chris R. Ruhl

RECEIVED
TECH CENTER 1600/2900
01 NOV -8 PM 1:14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Dominique P. BRIDON et al.

Serial No.: 09/623,548

Filing Date: September 5, 2000

For: PROTECTION OF ENDOGENOUS
THERAPEUTIC PEPTIDES FROM
PEPTIDASE ACTIVITY THROUGH
CONJUGATION TO BLOOD
COMPONENTS

Examiner: Lauren Wells

Group Art Unit: 1616

COMMUNICATION

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The undersigned thanks the Examiner for the phone call requesting a copy of the Information Disclosure Statement (IDS) originally filed February 26, 2001, in the above captioned application. In response to that conversation, Applicant submits a copy of the IDS with references, as filed February 26, 2001, for the Examiner's consideration.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for

any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 500862002100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: November 07, 2001

Respectfully submitted,

By: Michael R. Ward

Michael R. Ward
Registration No. 38,651

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6237
Facsimile: (415) 268-7522

COPY

PATENT
Docket No. 500862002100

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on February 26, 2001.

Lilia Olsen

RECEIVED
TFCH CENTER 1600/2990
01 NOV - 8 PM 1:14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

D. P. BRIDON et al.

Serial No.: 09/623,548

Filing Date: September 5, 2000

For: PROTECTION OF ENDOGENOUS
THERAPEUTIC PEPTIDES FROM
PEPTIDASE ACTIVITY THROUGH
CONJUGATION TO BLOOD
COMPONENTS

Examiner: To Be Assigned

Group Art Unit: 1646

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

***The document listed on the attached Form PTO-1449 is cited only. Applicants identify Applicants' related co-pending application Serial No. 09/657,276 filed September 7, 2000, for the Examiner's consideration.**

This Information Disclosure Statement is submitted:

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 500862002100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 26, 2001

Respectfully submitted,

By: Michael R. Ward
Michael R. Ward
Registration No. 38,651

Morrison & Foerster LLP
425 Market Street
San Francisco, California 94105-2482
Telephone: (415) 268-6237
Facsimile: (415) 268-7522

Form PTO-1449
(Rev. 7-80)U.S. Department of Commerce
Patent & Trademark OfficeATTY. DOCKET NO.
500862002100SERIAL NO.
09/623,548LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)APPLICANT
Bridon et al.

FILING DATE 9/5/2000

GROUP 1646

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	AA	4,462,941	07/1984	Lee et al.	260	112.5 R	
	AB	5,493,007	02/1996	Burnier et al.	530	317	
	AC	5,580,853	12/1996	Sytkowski	514	8	
	AD	5,612,034	03/1997	Pouletty et al.	424	184.1	
	AE	5,654,276	08/1997	Barrett et al.	514	13	
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AL	9325217	12/1993	PCT	A61K	37/00		
	AM	9510302	04/1995	PCT	A61K	39/395		
	AN	9606626	03/1996	PCT	A61K	38/00		
	AO	9924075	05/1999	PCT	A61K	47/48		
	AP	9924462	05/1999	PCT	C07K	02014/18		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Biotech Report, 1994/1995, 106-107
	AS	Proceedings of the 8 th American Peptide Symposium, 1983, 409-412
	AT	Int. J. Biochem. Cell. Biol., 1998, 30, 1281-1284

Examiner

Date considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Rev.7-80)	U.S. Department of Commerce Patent & Trademark Office	ATTY. DOCKETT NO. 500862002100	SERIAL NO. 09/623,548
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Bridon et al.	
		FILING DATE 09/05/2000	GROUP 1646

U.S. PATENT DOCUMENTS

*Examiner Initial	AA	Document Number	Date	Name	Class	Subclass	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AL	9948536	09/1999	PCT	A61K	47/48		
	AM	0 602 290	04/1999	EPO	A61K	47/48		
	AN							
	AO							
	AP							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Endocrinology, 1982, 110 (3), 1049-1051
	AS	J. Biol. Chem., 1995, 270 (43), 25344-25347
	AT	J. Dev. Physiol., 1989, 12, 55-62

Examiner	Date considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Rev.7-80)	U.S. Department of Commerce Patent & Trademark Office	ATTY. DOCKETT NO. 500862002100	SERIAL NO. 09/623,548
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Bridon et al.	
		FILING DATE 09/05/2000	GROUP 1646

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Anti-Cancer Drugs, 1997, 8, 677-685
	AS	Biopolymers (Peptide Science), 1998, 47, 451-463
	AT	Ann. Rev. Neurosci., 1984, 7, 223-255

Examiner	Date considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449
(Rev.7-80)U.S. Department of Commerce
Patent & Trademark OfficeATTY. DOCKETT NO.
500862002100SERIAL NO.
09/623,548LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)APPLICANT
Bridon et al.

FILING DATE 09/05/2000

GROUP 1646

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	AA*	09/657,276		BRIDON et al.			09/07/2000
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Chem. Pharm. Bull., 1979, 27 (8), 1942-1944
	AS	Proc. Natl. Acad. Sci., 1986, 83, 265-269
	AT	^{VOL. 10} TINS, 1993, 16, 403-409

Examiner

Date considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.